TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06989437: A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants Wit

Sponsor: Pfizer · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 982 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$676,368

Rescue Site Savings

+$450,912

Unlock Full NCT06989437 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06989437 Rescue Dossier →